Researchers from the College of Cologne’s Institute of Pathology at the University of Cologne and College Hospital Cologne, under the leadership of Dr. Yuri Tolkach and Professor Dr. Reinhard Büttner, have developed a digital pathology platform utilizing artificial intelligence. The platform leverages novel algorithms crafted in-house, enabling seamless, fully automated assessment of lung cancer patients’ tissue sections. The platform enables the rapid and precise analysis of digitized tissue samples on a computer, facilitating more efficient diagnosis of lung tumors. The examination ‘Subsequent Era Lung Most cancers Pathology: Improvement and Validation of Diagnostic and Prognostic Algorithms’ has been published in the journal.
Lung cancer is among the most common types of cancer affecting humans, with a remarkably high mortality rate. Currently, the choice of therapy for patients with lung cancer is primarily determined by pathological examination results. Pathologists can identify specific genetic alterations at a molecular level, enabling personalized treatment options. In recent years, the field of pathology has undergone a significant digital transformation. Because of this reason, microscopes are no longer in demand. Digital images of typical tissue sections are processed and then analyzed on a computer monitor. The application of advanced analytics, fueled by artificial intelligence, demands a foundation in digitalization to unlock its full potential. Utilizing advanced artificial intelligence capabilities, pathologists will be able to extract even more insightful information about cancer from histopathological tissue samples, a feat that would be impossible without the innovative power of AI technology?
“We also demonstrate the potential for our platform to facilitate the creation of innovative medical devices.” The advent of novel instruments can not only elevate the quality of analysis but also provide unprecedented insights into a patient’s disease progression, including how they respond to treatment, notes Dr. Yuri Tolkach, lead investigator from the Institute of Common Pathology and Pathological Anatomy at College Hospital Cologne.
To demonstrate the versatility of the platform, the analytics team will collaborate on a joint validation study with five leading pathology institutions in Germany, Austria, and Japan.
